Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics (Nasdaq: RVNC) have entered into an agreement whereby the companies seek to merge the two complementary organizations.
The news sent Revance’s shares rocket almost 87% to $6.60.
The combined company's flagship brands to include Daxxify (daxibotulinumtoxinA-lanm), the RHA Collection (filler), SkinPen (microneedling), PanOxyl (acne), Blue Lizar (sunscreen), and StriVectin (anti-aging). Daxxify competes with AbbVie's (NYSE: ABBV) blockbuster drug Botox (onabotulinumtoxinA).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze